Fleming CFO, Inc.

Financial decisions can make or break a startup. Get guidance from a fractional CFO to ensure your next move strengthens your life sciences company. Ready to navigate your finances with confidence? Get in touch today by visiting the link in the comments. #lifesciences | #startup | #biotech | #pharma | #medtech

The U.S. biopharma industry is one of the most competitive and capital-intensive sectors in the world. We listed key strategies for startup biotech and pharma companies to effectively manage their financial operations and position themselves for long-term success. View the link to our latest blog post in the comments. #biopharma | #biotech | #pharma | #startup

Macroeconomic pressures, the need for agility, and the rising complexity of clinical studies are driving the adoption of the Functional Service Provider (FSP) model in pharma. FSPs offer the flexibility and scalability needed to accelerate drug development and adapt to an evolving landscape. Parexel's EVP, Jenny Denney, discusses the benefits and considerations of using FSPs in life sciences in an interview with Pharmaceutical Executive. #pharma | #pharmaceuticalindustry | #lifesciences

Managing the finances of a growing life sciences company can be complex, especially when pitching to investors or scaling operations. From building detailed cash forecasting to delivering actionable strategic advice, our fractional CFOs ensure you're always prepared to talk to investors and navigate financial challenges. Discover how our expertise can help your business thrive: www.flemingcfo.com. #lifesciences | #pharma | #biotech | #medtech | #startup

As businesses seek agility and specialized expertise, fractional CFOs are becoming a go-to solution. These part-time financial leaders offer the strategic insights companies need without the full-time commitment, helping organizations navigate complex financial landscapes. Learn how a fractional CFO can benefit your company in an article from Fortune: #fractionalcfo | #cfo | #startup

Debut Biotechnology, after disrupting beauty with biomanufacturing, has secured a $2M contract with the Department of Defense to develop a bioindustrial manufacturing facility. This strategic shift highlights the immense growth potential of biotech beyond cosmetics. Curious how this pivot could inspire new avenues for your own startup? Read the full article for insights into how biotech innovation is reshaping industries, from beauty to national security. #biotech | #funding | #startup

Did you know that Fleming CFO also offers human resources support? See how your company can make optimal use of your most valuable asset - your people - without the overhead cost of a full-time HR specialist: https://bit.ly/3MGZDrV #hr | #startup | #lifesciences

With a Fed rate cut likely this month, the biotech industry might be on the verge of a major rebound. After years of underperformance, strong fundamentals and surging M&A activity could position the sector for serious growth. Get the full scoop on what’s driving biotech's next big wave from Pharmaceutical Executive. #biotech | #biotechindustry

It's great to see the ongoing thaw of the capital markets for biotechs. But it's still caveat emptor. Of the 18 biotech IPOs so far in 2024, more than half are currently trading below their offer price.

For biotech startups, raising non-dilutive capital can be a game-changer—but navigating the process can be complex. An article from SVB dives into how to secure these vital funds to fuel your innovation without giving up equity. #startup | #biotech | #capital | #funding